Table 3:
Men | Women | |||
---|---|---|---|---|
Model 14 | Model 25 | Model 14 | Model 25 | |
RR (95% CI)3 | RR (95% CI) 3 | RR (95% CI) 3 | RR (95% CI) 3 | |
Exposure Variable(s)6 | ||||
MVPA-SR (EU) | Model 1a | Model 2a | Model 1a | Model 2a |
T1 | Ref | Ref | Ref | Ref |
T2 | 1.24 (0.69–2.23) | 1.07 (0.74–1.55) | 0.88 (0.57–1.36) | 0.94 (0.69–1.29) |
T3 | 0.81 (0.41–1.60) | 0.82 (0.56–1.21) | 0.63 (0.38–1.07) | 0.93 (0.65–1.33) |
p for trend | 0.55 | 0.33 | 0.09 | 0.67 |
MVPA-Acc (mins/wk, cts>2020) | Model 1b | Model 2b | Model 1b | Model 2b |
T1 | Ref | Ref | Ref | Ref |
T2 | 0.44 (0.24–0.81) | 0.63 (0.44–0.90) | 0.52 (0.32–0.86) | 0.71 (0.52–0.97) |
T3 | 0.33 (0.17–0.67) | 0.52 (0.35–0.78) | 0.61 (0.34–1.08) | 0.71 (0.48–1.05) |
p for trend | 0.0007 | 0.0008 | 0.05 | 0.05 |
Both PA Measures | Model 1c | Model 2c | Model 1c | Model 2c |
MVPA-SR | ||||
T1 | Ref | Ref | Ref | Ref |
T2 | 1.31 (0.74–2.30) | 1.13 (0.78–1.64) | 0.94 (0.60–1.47) | 0.97 (0.70–1.33) |
T3 | 0.96 (0.50–1.84) | 0.90 (0.62–1.33) | 0.71 (0.41–1.26) | 1.04 (0.72–1.50) |
p for trend | 0.95 | 0.67 | 0.25 | 0.92 |
MVPA-Acc | ||||
T1 | Ref | Ref | Ref | Ref |
T2 | 0.45 (0.24–0.83) | 0.63 (0.44–0.91) | 0.55 (0.33–0.90) | 0.71 (0.52–0.97) |
T3 | 0.33 (0.17–0.65) | 0.55 (0.35–0.79) | 0.67 (0.37–1.22) | 0.70 (0.47–1.06) |
p for trend | 0.0006 | 0.001 | 0.12 | 0.05 |
Relative risk estimated from modified Poisson regression
Diabetes defined as fasting glucose≥7 mmol/l, 2 hour glucose tolerance test ≥ 11.1 mmol/l or HbA1c≥6.5% (48 mmol/mol IFCC (N=59 men, 88 women)
Based on those whose diabetes status at Years 25 or 30 could be ascertained (N=2000)
Adjusted for race, age, education, and Year 20 fasting glucose
Additionally adjusted for BMI
Three different PA exposure variables examined for each model: a) MVPA-SR only; b) MVPA-Acc only; and c) both MVPA-SR and MVPA-Acc, adjusted for each other